サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654322

上皮腫治療薬の世界市場：市場規模・シェア・動向分析 (種類別・薬剤クラス別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)

Epithelioma Treatment Market Size, Share & Trends Analysis Report By Type, By Drug Class (Hedgehog Pathway Inhibitors, Immune Checkpoint Inhibitors), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
上皮腫治療薬の世界市場：市場規模・シェア・動向分析 (種類別・薬剤クラス別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)
出版日: 2025年01月22日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

上皮腫治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の上皮腫治療薬の市場規模は、2025年から2030年にかけてCAGR 10.4%を記録し、2030年には97億3,000万米ドルに達する見込みです。

皮膚がん、特に基底細胞がん (BCC) と扁平上皮がん (SCC) の罹患率の増加が市場拡大の主な要因です。米国がん協会によると、米国では2024年に約100,640人の新規メラノーマ症例が発生すると予測されており、その内訳は男性が約59,170人、女性が約41,470人です。さらに、男性5,430人、女性2,860人を含む約8,290人が死亡すると予測されています。このような有病率の増加は、先進的な治療に対する需要の増加を裏付け、市場の成長に大きく寄与しています。

医療技術の進歩も重要な役割を果たしています。免疫チェックポイント阻害薬 (例：ペムブロリズマブ、ニボルマブ) や標的治療薬 (例：BCCに対するvismodegib) などの革新的な治療法の開発は、治療の選択肢を一変させ、患者に新たな希望をもたらし、市場機会を拡大しています。これらの進歩はさらに、これらの治療の有効性と安全性を強調する良好な臨床試験結果やFDAの承認によって支えられています。

規制機関や政府の取り組みも、市場の形成に極めて重要です。米国では、有望な治療法に対するFDAの早期承認プロセスが、新しい治療法への迅速なアクセスを促進しています。さらに、欧州では欧州医薬品庁 (EMA) のようなイニシアチブが、新薬の開発と承認に重要な支援を行っています。政府によるがん研究への資金援助や国民の意識向上キャンペーンは、早期発見・早期治療を強化し、市場の成長をさらに促進しています。

上皮腫治療薬市場：分析概要

  • 種類別では、基底細胞上皮腫が市場を独占し、2024年には61.0%のシェアを占めています。基底細胞上皮腫の一種であるBCCは、世界的に最も一般的な皮膚がんです。
  • 薬剤クラス別では、ヘッジホッグ経路阻害剤が2024年に41.2%以上の最大売上シェアを確保しました。この優位性は、BCC治療におけるこれらの阻害剤の有効性、皮膚がんの発生率の増加、最近の薬剤開発の著しい進展に起因します。
  • 販売チャネル別では、病院薬局セグメントが2024年に市場をリードし、51.8%以上の大幅な収益シェアを獲得しました。
  • 北米の上皮腫治療薬市場は2024年に37.5%の収益シェアで世界市場を独占し、主に皮膚がんの高い発生率と確立された医療インフラがその原動力となりました。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 上皮腫治療薬市場：変動要因・傾向・範囲

  • 市場連関の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • ビジネス環境分析
    • 業界分析：ポーターのファイブフォース分析
    • PESTEL分析

第4章 上皮腫治療薬市場：種類別のビジネス分析

  • 市場シェア：種類別 (2024年・2030年)
  • 種類別ダッシュボード
  • 市場規模の予測と動向分析：種類別 (2018～2030年)
  • 基底細胞上皮腫
  • 扁平上皮腫
  • その他

第5章 上皮腫治療薬市場：薬剤クラス別のビジネス分析

  • 市場シェア：薬剤クラス別 (2024年・2030年)
  • 薬剤クラス別ダッシュボード
  • 市場規模の予測と動向分析：薬剤クラス別 (2018～2030年)
  • ヘッジホッグ経路阻害剤
  • 免疫チェックポイント阻害剤
  • 化学療法剤
  • その他

第6章 上皮腫治療薬市場：流通チャネル別のビジネス分析

  • 市場シェア：流通チャネル別 (2024年・2030年)
  • 流通チャネル別ダッシュボード
  • 市場規模の予測と動向分析：流通チャネル別 (2018～2030年)
  • 病院薬局
  • 小売薬局
  • その他

第7章 上皮腫治療薬市場：地域別の推定・動向分析

  • 市場シェア：地域別 (2024年・2030年)
  • 市場ダッシュボード：地域別
  • 市場規模の予測と動向分析 (2018～2030年)
  • 北米
    • 国別 (2018～2030年)
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別 (2018～2030年)
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 国別 (2018～2030年)
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別 (2018～2030年)
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別 (2018～2030年)
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 参入企業の概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Bristol-Myers Squibb Company
    • Merck &Co., Inc.
    • Novartis AG
    • Amgen Inc.
    • Pfizer Inc.
    • Sanofi
    • Johnson &Johnson Services, Inc.
    • F. Hoffmann-La Roche Ltd
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global epithelioma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 5 Global epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 Global epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 North America epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 9 North America epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 North America epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 U.S epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 12 U.S epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 U.S Epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 Canada epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 15 Canada epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 Canada epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 18 Mexico epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 Mexico epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 22 Europe epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 Europe epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 UK epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 25 UK epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 UK Epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27 Germany epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 28 Germany epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Germany epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 France epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 31 France epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 France Epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Italy epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 34 Italy epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 Italy epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 37 Spain epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Spain epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Norway epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 40 Norway epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 41 Norway Epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Denmark epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 43 Denmark epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 44 Denmark epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Sweden epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 46 Sweden epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 Sweden epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Japan epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 53 Japan epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 Japan epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 China epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 56 China epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 57 China epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 India epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 59 India epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 India epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Australia epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 62 Australia epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 63 Australia epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 South Korea epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 65 South Korea epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 66 South Korea epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 68 Thailand epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 69 Thailand epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 72 Latin America epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 73 Latin America epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 75 Brazil epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 76 Brazil epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 78 Argentina epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 79 Argentina epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Epithelioma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 85 South Africa epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 86 South Africa epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 UAE epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 91 UAE epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 92 UAE epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait epithelioma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 94 Kuwait epithelioma treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 95 Kuwait epithelioma treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Epithelioma treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Type and drug class outlook (USD Million)
  • Fig. 10 Distribution channel outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Epithelioma treatment market dynamics
  • Fig. 13 Epithelioma treatment market: Porter's five forces analysis
  • Fig. 14 Epithelioma treatment market: PESTLE analysis
  • Fig. 15 Epithelioma treatment market: Type segment dashboard
  • Fig. 16 Epithelioma treatment market: Type market share analysis, 2024 & 2030
  • Fig. 17 Basal cell epithelioma market, 2018 - 2030 (USD Million)
  • Fig. 18 Squamous cell epithelioma market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Epithelioma treatment market: Drug class segment dashboard
  • Fig. 21 Epithelioma treatment market: Drug class market share analysis, 2024 & 2030
  • Fig. 22 Hedgehog pathway inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 23 Immune checkpoint inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 24 Chemotherapeutic agents market, 2018 - 2030 (USD Million)
  • Fig. 25 Others market, 2018 - 2030 (USD Million)
  • Fig. 26 Epithelioma treatment market: Distribution channel segment dashboard
  • Fig. 27 Epithelioma treatment market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 28 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 29 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 30 Others market, 2018 - 2030 (USD Million)
  • Fig. 31 Epithelioma treatment market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 North America epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. country dynamics
  • Fig. 36 U.S. epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada country dynamics
  • Fig. 38 Canada epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico country dynamics
  • Fig. 40 Mexico epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Europe epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 UK country dynamics
  • Fig. 43 UK epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Germany country dynamics
  • Fig. 45 Germany epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 France country dynamics
  • Fig. 47 France epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Italy country dynamics
  • Fig. 49 Italy epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain country dynamics
  • Fig. 51 Spain epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Norway country dynamics
  • Fig. 53 Norway epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Sweden country dynamics
  • Fig. 55 Sweden epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Denmark country dynamics
  • Fig. 57 Denmark epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Asia Pacific epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 Japan country dynamics
  • Fig. 60 Japan epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 China country dynamics
  • Fig. 62 China epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 India country dynamics
  • Fig. 64 India epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Australia country dynamics
  • Fig. 66 Australia epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea country dynamics
  • Fig. 68 South Korea epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 Thailand country dynamics
  • Fig. 70 Thailand epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 Latin America epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 Brazil country dynamics
  • Fig. 73 Brazil epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 Argentina country dynamics
  • Fig. 75 Argentina epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 MEA epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 77 South Africa country dynamics
  • Fig. 78 South Africa epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 79 Saudi Arabia country dynamics
  • Fig. 80 Saudi Arabia epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 81 UAE country dynamics
  • Fig. 82 UAE epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 83 Kuwait country dynamics
  • Fig. 84 Kuwait epithelioma treatment market, 2018 - 2030 (USD Million)
  • Fig. 85 Company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategic framework
目次
Product Code: GVR-4-68040-446-0

Epithelioma Treatment Market Growth & Trends:

The global epithelioma treatment market size is expected to reach USD 9.73 billion by 2030, registering a CAGR of 10.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing incidence of skin cancers, notably basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), is a major driver of market expansion. According to the American Cancer Society, the U.S. is expected to see approximately 100,640 new cases of melanoma in 2024, with around 59,170 in men and 41,470 in women. Additionally, melanoma is anticipated to cause about 8,290 deaths, including 5,430 men and 2,860 women. This escalating prevalence underscores the increasing demand for advanced treatments and contributes significantly to the market's growth.

Advancements in medical technology also play a crucial role. The development of innovative therapies, such as immune checkpoint inhibitors (e.g., pembrolizumab and nivolumab) and targeted therapies (e.g., vismodegib for BCC), has revolutionized treatment options, offering new hope for patients and expanding market opportunities. These advancements are further supported by positive clinical trial results and FDA approvals, which underscore the efficacy and safety of these treatments.

Regulatory bodies and government initiatives are also pivotal in shaping the market. In the U.S., the FDA's accelerated approval process for promising treatments facilitates faster access to new therapies. Additionally, initiatives like the European Medicines Agency (EMA) provide crucial support in developing and approving new drugs in Europe. Government funding for cancer research and public awareness campaigns are enhancing early detection and treatment, further driving market growth.

Epithelioma Treatment Market Report Highlights:

  • Based on type, basal cell epithelioma dominated the market and accounted for a share of 61.0% in 2024. BCC, a type of basal cell epithelioma, is the most common form of skin cancer globally.
  • Based on drug class, the hedgehog pathway inhibitors segment secured the largest revenue share of over 41.2% in 2024. This prominence is attributed to the efficacy of these inhibitors in treating BCC, the increasing incidence of skin cancers, and significant recent advancements in drug development.
  • Based on distribution channel, The hospital pharmacies segment led the market in 2024, capturing a substantial revenue share of over 51.8%.
  • North America epithelioma treatment market dominated the global market with a revenue share of 37.5% in 2024, largely fueled by the high incidence of skin cancers and a well-established healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug Class
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Epithelioma Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Epithelioma Treatment Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Basal Cell Epithelioma
    • 4.4.1. Basal Cell Epithelioma Market, 2018 - 2030 (USD Million)
  • 4.5. Squamous Cell Epithelioma
    • 4.5.1. Squamous Cell Epithelioma Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Epithelioma Treatment Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 5.4. Hedgehog Pathway Inhibitors
    • 5.4.1. Hedgehog Pathway Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.5. Immune Checkpoint Inhibitors
    • 5.5.1. Immune Checkpoint Inhibitors Market, 2018 - 2030 (USD Million)
  • 5.6. Chemotherapeutic Agents
    • 5.6.1. Chemotherapeutic Agents Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Epithelioma Treatment Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Epithelioma Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 7.4. North America
    • 7.4.1. North America Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Epithelioma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Epithelioma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Bristol-Myers Squibb Company
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Merck & Co., Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Novartis AG
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Amgen Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Sanofi
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Johnson & Johnson Services, Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. F. Hoffmann-La Roche Ltd
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives